License & Collaboration Revenue was Vir Biotechnology’s largest product and service line in fiscal 2025, bringing in $63.13M of $68.56M (92%).
| Product and Service | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Contract Revenue | — | — | — | — | ||
| License & Collaboration Revenue | $37.38M | — | $61.37M | $63.13M | ||
| Antibody Program | — | — | — | — | ||
| Grant Revenue | $46.69M | — | $10.49M | $2.04M | ||
| Other Revenue | $2.11M | $51.70M | $2.34M | $3.39M | ||
| Total | $86.18M | $51.70M | $74.21M | $68.56M |
Vir Biotechnology brought in $68.56M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 7.6% from $74.21M in fiscal 2024. License & Collaboration Revenue was the largest at $63.13M (92.1%), ahead of Other Revenue at $3.39M (4.9%) and Grant Revenue at $2.04M (3.0%).
Compared with fiscal 2024, Other Revenue grew fastest, up 44.7% to $3.39M, while Grant Revenue fell the most, down 80.6% to $2.04M. From fiscal 2023 to 2025, combined revenue from these lines fell from $86.18M to $68.56M, a compound annual decline of 10.8%. License & Collaboration Revenue's share of the total rose from 43.4% to 92.1%.
Foreign Customers was Vir Biotechnology’s largest region in fiscal 2025, bringing in $64.27M of $66.30M (97%).
| Geography | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Foreign Customers | $1.55B | $37.27M | $60.31M | $64.27M |
| U.S. Customers | $39.70M | $47.14M | $11.53M | $2.04M |
| Total | $1.59B | $84.40M | $71.83M | $66.30M |
Vir Biotechnology brought in $66.30M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 7.7% from $71.83M in fiscal 2024. Foreign Customers was the largest at $64.27M (96.9%), ahead of U.S. Customers at $2.04M (3.1%).
Compared with fiscal 2024, Foreign Customers grew 6.6% to $64.27M, while U.S. Customers fell 82.3% to $2.04M. From fiscal 2022 to 2025, combined revenue from these regions fell from $1.59B to $66.30M, a compound annual decline of 65.3%. Foreign Customers' share of the total fell from 97.5% to 96.9%.
Norgine was Vir Biotechnology’s largest revenue line in fiscal 2025, bringing in $64.27M of $67.66M (95%).
| Customer | FY 2025 |
|---|---|
| Norgine | $64.27M |
| Other | $3.39M |
| Total | $67.66M |
Vir Biotechnology brought in $67.66M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Norgine was the largest at $64.27M (95.0%), ahead of Other at $3.39M (5.0%).
Vir Biotechnology (VIR) reports its revenue by product and service, by geography and by customer. In fiscal 2025, License & Collaboration Revenue was its largest product and service line, bringing in $63.13M (92.1% of the total), followed by Other Revenue at $3.39M (4.9%).
License & Collaboration Revenue was Vir Biotechnology's largest product and service line in fiscal 2025, bringing in $63.13M, or 92.1% of the $68.56M total across its three product and service lines.
Foreign Customers was Vir Biotechnology's largest region in fiscal 2025, bringing in $64.27M, or 96.9% of the $66.30M total across its two regions.
Norgine was Vir Biotechnology's largest revenue line in fiscal 2025, bringing in $64.27M, or 95.0% of the $67.66M total across its two revenue lines.
Among Vir Biotechnology's product and service lines that make up at least 2% of revenue, Other Revenue grew fastest in fiscal 2025, up 44.7% from $2.34M to $3.39M.
Every figure comes from Vir Biotechnology's annual financial filings, as reported. Each line keeps the name Vir Biotechnology gives it, and years follow its fiscal calendar.
Vir Biotechnology's revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.